However, there are multiple lines of evidence to suggest that cancers can use the INSR/IGF1R pathway as a resistance mechanism to other treatments and that IGF1R inhibition can augment responses to standard chemo‐ and radiotherapy. This evidence concerns the gene IGF1R and cancer.